U.S. Markets closed

A Focus on Pipeline Expansion Bodes Well for Athenex

Kenneth Smith
A Focus on Pipeline Expansion Bodes Well for Athenex

Athenex entered a joint venture with Xiangxue Life Sciences for developing and commercializing T-cell receptor engineered cells (or TCR-T). TCR-T is a cancer immunotherapy technology based on the novel approach to high-affinity TCR developed by Xiangxue Life Sciences.